These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 12171485)

  • 1. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
    MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.
    MacMillan ML; Weisdorf DJ; Davies SM; DeFor TE; Burns LJ; Ramsay NK; Wagner JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(1):40-6. PubMed ID: 11858189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unrelated cord blood transplant experience by the pediatric blood and marrow transplant consortium.
    Yu LC; Wall DA; Sandler E; Chan KW; Grayson G; Kletzel M
    Pediatr Hematol Oncol; 2001 Jun; 18(4):235-45. PubMed ID: 11400647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease.
    Chopra Y; Acevedo K; Muise A; Frost K; Schechter T; Krueger J; Ali M; Chiang KY; Kim VH; Grunebaum E; Wall D
    Transplant Cell Ther; 2024 May; 30(5):546.e1-546.e7. PubMed ID: 38458476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
    Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
    Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
    Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
    Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
    Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin.
    Sedlácek P; Formánková R; Keslová P; Srámková L; Hubácek P; Król L; Kulich M; Starý J
    Bone Marrow Transplant; 2006 Dec; 38(11):745-50. PubMed ID: 17041606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients.
    Boiron JM; Lerner D; Pigneux A; Fabères C; Bordessoule D; Turlure P; Cony-Makhoul P; Hau F; Dazey B; Agape P; Reiffers J; Marit G
    Leuk Lymphoma; 2001 Apr; 41(3-4):285-96. PubMed ID: 11378541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
    Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Bacigalupo A; Van Lint MT; Occhini D; Margiocco M; Ferrari G; Pittaluga PA; Frassoni F; Peralvo J; Lercari G; Carubia F
    Transplantation; 1988 Jun; 45(6):1091-4. PubMed ID: 3289150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease.
    Martinez CA; Shah S; Shearer WT; Rosenblatt HM; Paul ME; Chinen J; Leung KS; Kennedy-Nasser A; Brenner MK; Heslop HE; Liu H; Wu MF; Hanson IC; Krance RA
    J Allergy Clin Immunol; 2012 Jan; 129(1):176-83. PubMed ID: 22078471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose.
    Dominietto A; Raiola AM; van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Frassoni F; Casarino L; Verdiani S; Bacigalupo A
    Br J Haematol; 2001 Jan; 112(1):219-27. PubMed ID: 11167808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.